Recent research into retatrutide peptide highlight promising outlook for managing obesity and type disease. The peptide, a dual agonist of GLP-1 receptor and GIP, seems to offer greater weight reduction and glycemic control compared existing therapies. Additional patient studies are needed to completely evaluate its well-being history and sustained